8-K 1 ea140433-8k_blondertongue.htm FORM 8-K

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 5, 2021

 

Blonder Tongue Laboratories, Inc.

(Exact Name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation)

1-14120

(Commission File Number)

52-1611421

(I.R.S. Employer
Identification No.)

 

  One Jake Brown Road, Old Bridge, New Jersey  08857

(Address of principal executive offices) (Zip Code)

 

  Registrant’s telephone number, including area code: (732) 679-4000  

 

Not Applicable

(Former name or former address, if changed since last report)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock, par value $.001   BDR   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

  

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As previously reported, on January 8, 2021, the Compensation Committee and the Board of Directors of Blonder Tongue Laboratories, Inc. (the "Company") determined to adjust the compensation of certain of the Company's executive officers, including Edward R. Grauch, the Company's President and Chief Executive Officer. The adjustment of Mr. Grauch's compensation consisted of a 25% reduction in his gross salary, which began with the pay period that commenced December 27, 2020 and was to continue thereafter through and including December 31, 2021. On May 5, 2021, the Compensation Committee made certain revisions to Mr. Grauch's compensation, providing that the previously-implemented 25% reduction will be changed temporarily to a 10% reduction for two pay periods to occur prior to the end of June 2021, after which the 25% reduction will resume and continue thereafter through and including December 31, 2021, unless otherwise subsequently adjusted by action of the Compensation Committee and/or the Board of Directors.

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BLONDER TONGUE LABORATORIES, INC.
   
  By:  /s/ Eric Skolnik
  Eric Skolnik
Senior Vice President and Chief Financial Officer

 

Date: May 6, 2021